RE: Probabilistic model

From: "Mats Karlsson" Subject: RE: [NMusers] Probabilistic model Date: Wed, May 18, 2005 3:03 am Hi Nick, The primary endpoints of sildenafil were six-category scales. The statistical analysis plan said that these were to be treated as continuous endpoints. Therefore in the PKPD analysis we (Peter Milligan, Scott Marshall and I) analysed them as such but also as categorical endpoints. I have to say that model development as categorical data was considerably simpler than that as continuous. However, in the end there were no differences in conclusions between the two approaches when based on simulations from the two models. This was presented at PAGE in 1999. I can probably find you the presentation if you're interested. Best regards, Mats -- Mats Karlsson, PhD Professor of Pharmacometrics Div. of Pharmacokinetics and Drug Therapy Dept. of Pharmaceutical Biosciences Faculty of Pharmacy Uppsala University Box 591 SE-751 24 Uppsala Sweden phone +46 18 471 4105 fax +46 18 471 4003 mats.karlsson@farmbio.uu.se